Navigation Links
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Date:9/26/2007

Characterization of Receptor's Central Role in Cancer is Published in the

Proceedings of the National Academy of Sciences

MOUNTAIN VIEW, Calif., Sept. 26 /PRNewswire/ -- ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics that target the chemokine system, today announced the publication of data from a series of rigorous experiments to elucidate CXCR7's essential role in the progression and development of certain cancers. CXCR7 is a novel chemokine receptor whose function was discovered and characterized by ChemoCentryx.

ChemoCentryx scientists, joined by researchers from the University of Michigan and the Iowa State University, found that CXCR7 plays a crucial role in both tumor development and progression by enabling cancer cell survival and promoting the process of angiogenesis (the growth of new blood vessels). Importantly, CXCR7 can be readily detected on many primary human tumor tissue samples (such as breast and lung cancers), but CXCR7 is not expressed by surrounding healthy tissue. Findings from the company's research are presented in an article titled "CXCR7 promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature" in the September 26, 2007 Early Edition and October 2, 2007 print edition of the Proceedings of the National Academy of Sciences (PNAS).

"Our labs were thrilled to have the opportunity to collaborate in support of ChemoCentryx's ground-breaking research on CXCR7," said Gary D. Luker, M.D., Assistant Professor, Department of Radiology, Department of Microbiology and Immunology, University of Michigan Medical School. "With broad implications of targeting CXCR7 for cancer treatment, this work exemplifies how great science, done well, may lead directly to the discovery and development of new medicines."

"These data represent a significant scientific finding with potentially profound clinical
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
3. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
4. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
5. Gene-Specific Primers for NMDA Receptor Subunits
6. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
7. Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer
8. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
9. Performance of Ad-A-Gene EGFP-Glucocorticoid Receptor (EGFP-GCCR): an adenoviral vector gene delivery system
10. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today ... 2014. Biorem,s complete fiscal 2014 year-end financial statements and MD&A have been ... , 2013 , 2014 , 2013 Revenue ... 19,596 Gross profit 1,326 , 1,703 , 2,231 ... 1,493 , 3,377 , 4,562 Ebitda* 92 ...
(Date:4/29/2015)... 2015 Cambrex Corporation (NYSE: CBM ) announced ... Friday, May 1, 2015 before the market opens. , ... host a conference call to discuss the financial results. First ... , Friday, May 1, 2015 at 8:30 a.m. Eastern ... U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem ... cell therapy has processed more than 11,000 samples. ... successful treatment for horses with potentially fatal injuries to ... worldwide exclusive license for adipose-derived (fat derived) stem cell ... treated in January 2004. Shortly after, the first dogs ...
(Date:4/29/2015)... - Northern Biologics Inc., a privately held biotechnology company ... strategic collaboration with Celgene Corporation.  As part of ... upfront cash payment. It will use the funds ... will have the right to receive additional future ... Under the agreement, Northern Biologics ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... predicting and quashing environmental decoherence, a phenomenon that has proven ... the way of quantum computing. The findings based ... and confirmed by experiments at the University of California Santa ... of the journal Nature . Quantum mechanics states ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
... July 20, 2011 ReSearch Pharmaceutical Services, Inc. ... global Phase II-IV clinical development solutions to the ... following key additions to its Operational and Senior ... Davis, II, as Chief Information Officer and Executive ...
Cached Biology Technology:Discovery may overcome obstacle for quantum computing 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... 26, 2011Magnetic resonance tractography (MRT) is a valuable, ... and, as MRT methods and technologies advance, has ... on brain activity and connectivity. Critical information about ... explored in a forward-looking review article in the ...
... Texas at Austin researchers have discovered how to extract and ... objects are from the focus distance, a feat only accomplished ... Like a camera, the human eye has an auto-focusing system, ... humans do not require trial and error to focus an ...
... used local anesthetic, may more easily wiggle into a ... compounds that carry a negative charge, a new study ... more complete understanding of the molecular-level mechanisms behind pain-blocking ... use. Most scientists believe that local anesthetics prevent ...
Cached Biology News:Researchers develop optimal algorithm for determining focus error in eyes and cameras 2
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: